Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Aims

To assess effectiveness, cost, and cost-effectiveness of ranibizumab versus the current medical practices of treating age-related macular degeneration in France.

Methods

A simulation decision framework over 1 year compared ranibizumab versus the usual care using two effectiveness criteria: the “visual acuity improvement rate” (greater than 15 letters on the ETDRS scale) and the “rate of legal blindness avoided”. Two decision trees included various sequences of current treatments, with or without ranibizumab.

Results

Ranibizumab appeared significantly more effective than the usual care (p < 0.001), providing greater treatment success rate of visual acuity improvement (48.8% versus 33.9%). The cost of the ranibizumab strategy was higher (9,123 euros (€) over 1 year for ranibizumab versus 7,604 € for the usual care) but the average cost-effectiveness was lower – 18,721 € /success for ranibizumab versus 22,543 €/success for usual care (p < 0.001). Considering the “legal blindness avoided” success criterion, the ranibizumab strategy appeared significantly more effective (p < 0.001), providing greater treatment success rate for of legal blindness avoided than usual care (99.7% versus 93.1%) although it was more expensive (9,196 € over 1 year for ranibizumab versus 5,713 € for the usual care).

Conclusion

Ranibizumab significantly improved the rate of visual acuity improvement and reduced the rate of legal blindness. Ranibizumab appeared significantly more cost-effective than the usual treatments in terms of visual acuity improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chaine G, Rohart C (2007) Epidemiology and risk factors for age-related macular degeneration. J Fr Ophtalmol 30:74

    Article  Google Scholar 

  2. Ambati J, Ambati B, Yoo S, Ianchulev S, Adamis A (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293

    Article  PubMed  Google Scholar 

  3. Ferris FL, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102(11):1640–1642 Nov

    Article  PubMed  Google Scholar 

  4. Pina JP, Offret H, Labetoulle M (2007) Les nouveaux traitements de la DMLA. Medecine 3(10):443–445

    Google Scholar 

  5. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  6. Rosenfeld PJ, Heier JS, Hantsbatger G, Shams N (2006) Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113:632

    Article  Google Scholar 

  7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, for the Marina Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. New Eng J Med 355:1419–1431

    Article  PubMed  CAS  Google Scholar 

  8. Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141–148

    Article  PubMed  CAS  Google Scholar 

  9. Rajczi A (2007) A critique of the innovation argument against a national health program. Bioethics 21(6):316–323 Jul

    Article  PubMed  Google Scholar 

  10. Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24(11):1043–1053

    Article  PubMed  Google Scholar 

  11. Polsky D, Glick HA, Wilke R, Schulman K (1997) Confidence Intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 6:243–252

    Article  PubMed  CAS  Google Scholar 

  12. Kegan B, West RW (2005) Modeling the simple epidemic with deterministic differential equations and random initial conditions. Math Biosci 195(2):179–193

    Article  PubMed  Google Scholar 

  13. Takeda AL, Colquitt JL, Clegg AJ, Jones J (2007) Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 91(9):1177–1182

    Article  PubMed  CAS  Google Scholar 

  14. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361–372

    PubMed  Google Scholar 

  15. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4):642.e1–4. Epub 2006 Feb 14.

    Article  Google Scholar 

  16. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 11

  17. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupD’Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6):992–1001

    Article  PubMed  Google Scholar 

  18. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD (2005) Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10):1747–1757

    Article  PubMed  Google Scholar 

  19. Macugen AMD Study Group (2007) Pegaptanib 1-Year Systemic Safety Results from a Safety-Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology 114(9):1702–1712

    Article  Google Scholar 

  20. Schmidt-Erfurth U (1998) Photodynamic therapy. Minimally invasive treatment of choroidal neovascularisation. Ophthalmology 95:725–731

    Article  CAS  Google Scholar 

  21. Kaiser PK (2006) Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open label extension. Graefe Arch Clin Exp Ophthalmol 244:1132–1142

    Article  CAS  Google Scholar 

  22. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G (2006) Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 142(6):1072–1074

    Article  PubMed  CAS  Google Scholar 

  23. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR (2005) Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 40(3):277–287

    PubMed  Google Scholar 

  24. Brown GC, Brown MM, Brown H, Godshalk AN (2007) Pharmacoeconomics and macular degeneration. Curr Opin Ophthalmol 18(3):206–211

    Article  PubMed  Google Scholar 

  25. Raftery J, Clegg A, Jones J, Tan SC, Lotery A (2007) Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness. Br J Ophthalmol 91(9):1244–1246

    Article  PubMed  Google Scholar 

  26. Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N (2002) Limitations of the methods used for calculating quality-adjusted life years values. Pharmacoeconomics 20(7):463–473

    Article  PubMed  Google Scholar 

  27. McGregor M, Caro JJ (2006) QALYs: are they helpful to decision-makers? Pharmacoeconomics 24(10):947–952

    Article  PubMed  Google Scholar 

  28. Bremond-Gignac D, Tixier J, Missotten T, Laroche L, Beresniak A (2002) Evaluation of the quality of life in ophthalmology. Presse Med 19;31(34):1607–1612

    Google Scholar 

Download references

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Author information

Authors and Affiliations

  1. Centre Ophtalmologique d’Imagerie et de Laser, Paris, France

    S. Y. Cohen & G. Quentel

  2. Department of Ophthalmology, Hôpital Robert Debré, APHP and Paris 7 University, INSERM UMRS592, Paris, France

    D. Bremond-Gignac

  3. Department of Ophthalmology, Hôpital Intercommunal, APHP, and Paris 12 University, Créteil, France

    G. Mimoun

  4. Novartis Groupe France S.A., Rueil-Malmaison, France

    T. Citterio & S. Bisot-Locard

  5. LIRAES, University Paris-Descartes, Paris, France

    A. Beresniak

  6. Data Mining International, Geneva, Switzerland

    A. Beresniak

Authors
  1. S. Y. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Bremond-Gignac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Quentel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Mimoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Citterio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Bisot-Locard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Beresniak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Bremond-Gignac.

Additional information

Financial relationships: This study was sponsored by Novartis Pharma SAS, France. The authors have no financial interests with the sponsor and have full control of all primary data. Thomas Citterio and Ségolène Bisot-Locard are employees of Novartis, France. The authors agree to allow Graefes Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, S.Y., Bremond-Gignac, D., Quentel, G. et al. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246, 1527–1534 (2008). https://doi.org/10.1007/s00417-008-0890-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0890-8

Keywords

Search

Navigation